A
ELVN icon

AJOVista’s Enliven Therapeutics ELVN Stock Holding History

AJOVista’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,046
Closed -$28.3K – 181
2023
Q4 		$28.3K Buy
+2,046
New +$25K 0.04% 338

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

AJOVista's ELVN Position: Q1 2024 in Review

AJOVista sold out of Enliven Therapeutics (ELVN) in Q1 2024, closing a stake of 2,046 shares — an estimated $28.3K sold.

AJOVista first reported a position in ELVN in Q4 2023 and held it in 1 quarter. The position peaked at $28.3K in Q4 2023. 74 funds tracked by Wall St. Rank hold ELVN as of Q1 2024.

  • AJOVista reported no remaining Enliven Therapeutics position as of Q1 2024 after selling out during the quarter.
  • AJOVista sold 2,046 Enliven Therapeutics shares in Q1 2024, an estimated $28.3K.
  • AJOVista first reported a position in Enliven Therapeutics in Q4 2023 and held it in 1 quarter.
  • AJOVista's Enliven Therapeutics position peaked at $28.3K in Q4 2023.
  • 74 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.